Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Current guidelines for chemoembolization for hepatocellular carcinoma: Room for improvement?

White JA, Gray SH, Li P, Simpson HN, McGuire BM, Eckhoff DE, Abdel Aal AMK, Saddekni S, Dubay DA.

Hepatol Commun. 2017 May 18;1(4):338-346. doi: 10.1002/hep4.1046. eCollection 2017 Jun.

2.

Improving Quality of Care in Patients with Liver Cirrhosis.

Saberifiroozi M.

Middle East J Dig Dis. 2017 Oct;9(4):189-200. doi: 10.15171/mejdd.2017.73. Review.

3.

T2* Mapping from Multi-Echo Dixon Sequence on Gadoxetic Acid-Enhanced Magnetic Resonance Imaging for the Hepatic Fat Quantification: Can It Be Used for Hepatic Function Assessment?

Yoo H, Lee JM, Yoon JH, Kang HJ, Lee SM, Yang HK, Han JK.

Korean J Radiol. 2017 Jul-Aug;18(4):682-690. doi: 10.3348/kjr.2017.18.4.682. Epub 2017 May 19.

4.

Bacterial load and cytokine profile in patients with cirrhosis following therapy with proton pump inhibitors: a prospective cohort study.

Triantos C, Kalafateli M, Spantidea PI, Goukos D, Koutroumpakis E, Konstantakis C, Assimakopoulos SF, Gogos C, Mouzaki A, Daikos G, Thomopoulos K.

Ann Gastroenterol. 2017;30(4):450-456. doi: 10.20524/aog.2017.0142. Epub 2017 Apr 6.

5.

The importance of a multidisciplinary approach to hepatocellular carcinoma.

Siddique O, Yoo ER, Perumpail RB, Perumpail BJ, Liu A, Cholankeril G, Ahmed A.

J Multidiscip Healthc. 2017 Mar 20;10:95-100. doi: 10.2147/JMDH.S128629. eCollection 2017. Review.

6.
7.

Palliative Care Quality Indicators for Patients with End-Stage Liver Disease Due to Cirrhosis.

Walling AM, Ahluwalia SC, Wenger NS, Booth M, Roth CP, Lorenz K, Kanwal F, Dy S, Asch SM; Palliative Care Cirrhosis Quality Expert Panel.

Dig Dis Sci. 2017 Jan;62(1):84-92. doi: 10.1007/s10620-016-4339-3. Epub 2016 Nov 1.

8.

Siglec-7 as a Novel Biomarker to Predict Mortality in Decompensated Cirrhosis and Acute Kidney Injury.

Allegretti AS, Ortiz G, Kalim S, Wibecan J, Zhang D, Shan HY, Xu D, Chung RT, Karumanchi SA, Thadhani RI.

Dig Dis Sci. 2016 Dec;61(12):3609-3620. Epub 2016 Sep 21.

9.

Repurposing of approved cardiovascular drugs.

Ishida J, Konishi M, Ebner N, Springer J.

J Transl Med. 2016 Sep 20;14:269. doi: 10.1186/s12967-016-1031-5. Review.

10.

The Effect of the Gelatinous Lactulose for Postoperative Bowel Movement in the Patients Undergoing Cesarean Section.

Shigemi D, Nakanishi K, Miyazaki M, Shibata Y, Suzuki S.

Int Sch Res Notices. 2014 Oct 29;2014:752862. doi: 10.1155/2014/752862. eCollection 2014.

11.

Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.

Jwa HY, Cho YK, Choi EK, Kim HU, Song HJ, Na SY, Boo SJ, Jeong SU, Kim BS, Lee BW, Song BC.

Clin Mol Hepatol. 2016 Mar;22(1):183-7. doi: 10.3350/cmh.2016.22.1.183. Epub 2016 Mar 28.

12.

A profile of volatile organic compounds in exhaled air as a potential non-invasive biomarker for liver cirrhosis.

Pijls KE, Smolinska A, Jonkers DM, Dallinga JW, Masclee AA, Koek GH, van Schooten FJ.

Sci Rep. 2016 Jan 29;6:19903. doi: 10.1038/srep19903.

13.

Changes in Hospital Admissions and Mortality for Complications of Cirrhosis: Implications for Clinicians and Health Systems.

Ho SB, Matheny ME, Schnabl BE.

Gut Liver. 2016 Jan;10(1):8-9. doi: 10.5009/gnl15593. No abstract available.

14.

Development of risky varices in alcoholic cirrhosis with a well-maintained nutritional status.

Enomoto H, Sakai Y, Iwata Y, Takata R, Aizawa N, Ikeda N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Ishii A, Takashima T, Nishikawa H, Iijima H, Nishiguchi S.

World J Hepatol. 2015 Sep 28;7(21):2358-62. doi: 10.4254/wjh.v7.i21.2358.

15.

A Complex Multiherbal Regimen Based on Ayurveda Medicine for the Management of Hepatic Cirrhosis Complicated by Ascites: Nonrandomized, Uncontrolled, Single Group, Open-Label Observational Clinical Study.

Patel MV, Patel KB, Gupta S, Michalsen A, Stapelfeldt E, Kessler CS.

Evid Based Complement Alternat Med. 2015;2015:613182. doi: 10.1155/2015/613182. Epub 2015 Aug 3.

16.

(1)H nuclear magnetic resonance spectroscopy-based metabonomic study in patients with cirrhosis and hepatic encephalopathy.

Dabos KJ, Parkinson JA, Sadler IH, Plevris JN, Hayes PC.

World J Hepatol. 2015 Jun 28;7(12):1701-7. doi: 10.4254/wjh.v7.i12.1701.

17.

Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis.

Iwata K, Enomoto H, Nishiguchi S, Aizawa N, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Takashima T, Saito M, Imanishi H, Iijima H, Tsuda Y, Higuchi K.

J Clin Biochem Nutr. 2014 Sep;55(2):147-52. doi: 10.3164/jcbn.14-33. Epub 2014 Jul 26.

18.

Management of variceal and nonvariceal upper gastrointestinal bleeding in patients with cirrhosis.

Cremers I, Ribeiro S.

Therap Adv Gastroenterol. 2014 Sep;7(5):206-16. doi: 10.1177/1756283X14538688. Review.

19.

Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis.

Qi XS, Bai M, Fan DM.

World J Gastroenterol. 2014 Aug 28;20(32):11463-6. doi: 10.3748/wjg.v20.i32.11463.

20.

Diagnosis of spontaneous bacterial peritonitis and an in situ hybridization approach to detect an "unidentified" pathogen.

Enomoto H, Inoue S, Matsuhisa A, Nishiguchi S.

Int J Hepatol. 2014;2014:634617. doi: 10.1155/2014/634617. Epub 2014 Jul 15. Review.

Supplemental Content

Support Center